Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Chevron’s Q4 Release Reveals Mixed Results – $CVX $DIA $INVO

By John F. Heerdink, Jr.

As per reports, Chevron Corporation (CVX) quarterly release reported mixed Q4 results, as it missed on earnings but exceeded revenue estimates. Recently, the company announced its $75 billion stock buyback program, which represents 20% of shares outstanding at current price levels, and it also boosted its quarterly dividend by 6%, to $1.51 a share. 

Fourth Quarter  Highlights:

  • The oil major reported a 60% earnings jump, to $4.09 per share, whereas Wall Street predicted EPS growing 69% to $4.33. 
  • Revenue increased 17% to $56.47 billion.
  • Full-year earnings in 2022 soared 128% to $18.83 per share while sales increased 51% to $246.25 billion.
  • Cash flow from operations in 2022 totaled $49.6 billion, compared with $29.2 billion in 2021.

“We delivered record earnings and cash flow in 2022, while increasing investments and growing U.S. production to a company record. We are well positioned to lead in both traditional and new energy businesses, while delivering higher returns, lower carbon and superior shareholder value,” stated CEO Mike Wirth.

Dow 30 component Chevron Corporation (CVX), through its subsidiaries, engages in integrated energy, chemicals, and petroleum operations worldwide.  To learn more about Chevron (CVX) and to track their progress please visit the Vista Partners Chevron Page.


Fertility rates have hit a record low in the United States. The latest US government fertility statistics come from 2019, and they estimate there were 58.2 births year per 1,000 women of childbearing age (defined by the CDC as women between ages 15 and 44).

If you have ever struggled with infertility issues, or know someone who has, you are probably well aware of how demoralizing it can be. Imagine for a moment spending thousands of dollars and months of intensive medical procedure only to end up empty handed, exhausted, sad, and defeated because after all of that time, work, and money, you still don’t have a baby. That’s an incredibly difficult situation, and it’s becoming more common each passing year. Likewise, the need for more effective, less invasive infertility treatment options is increasing with each passing year. This is the sole focus of medtech company INVO Bioscience (NASDAQ: INVO). Learn more by reading the following story that we published recently. 

INVO Bioscience (NASDAQ: $INVO), A Company Seeking To Address A Massively Underserved Fertility Market

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also provides select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives. 


Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.

(Read Original Story: Chevron Reports Record Profits, $75 Billion Buyback; White House Fumes in Investor's Business Daily)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us